Gilead Sciences, Inc.

Jason K Perry

Kevin S Currie

Peter A Blomgren

Jeffrey E Kropf

Zhongdong Zhao

Leena Patel

Christopher T Clark

Kirk L Stevens

Jayaraman Chandrasekhar

Yasamin Moazami

Nicole Nava

Taryn Campbell

Natalie Seeger

Jennifer Anne Treiberg

Suet Chung Yeung

Julian Andrew Codelli

Stephane Perreault

Kassandra F Sedillo

Julian A Codelli

Suet C Yeung

Richard L Mackman

Scott D Schroeder

James Ming Chen

Eda Y Canales

Devan Naduthambi

Oliver L Saunders

Michael R Mish

Gregory F Chin

Joshua J Van Veldhuizen

Stephen E Ammann

Alan X Huang

Weng K Chang

Henok H Kinfe

Christopher J Swank

Jessica L McKinley

Xinpei Cai

Kevin X Rodriguez

Choung U Kim

Scott E Lazerwith

Kuei-Ying Lin

David A Oare

Jay P Parrish

Sundaramoorthi Swaminathan

Lijun Zhang

Constantine G Boojamra

David Sperandio

The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

Sars-cov2 main protease inhibitors

SARS-COV2 main protease inhibitors

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

Quinoline derivatives

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), therapeutic methods for treating inflammatory disease.

Compounds for inhibition of &#x3b1;4 &#x3b2;7 integrin

Compounds for inhibition of alpha 4 beta 7 integrin

Compounds for inhibition of &#x3b1;4&#x3b2;7 integrin

Imidazopyridine derivatives

The invention provides unsaturated phosphonates of Formula I or a tautomer or pharmaceutically acceptable salt thereof, as described herein, as well as pharmaceutical compositions comprising the compounds, and therapeutic methods comprising administering the compounds. The compounds have anti-viral properties and are useful for treating viral infections (e.g. HCV) in animals (e.g. humans). 

Nucleoside analogs for antiviral treatment

A compound of Formula I, Formula II, Formula III, or Formula IV: or a pharmaceutically acceptable salt, solvate, and/or ester thereof, therapeutic compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

Phosphonate inhibitors of HCV

Growing community of inventors

San Francisco, CA, United States of America

Jason K Perry